| Literature DB >> 25957661 |
Hong-Yan Lin1, Zi-Kang Li1, Li-Fei Bai2, Shahla Karim Baloch1, Fang Wang1, Han-Yue Qiu1, Xue Wang1, Jin-Liang Qi1, Raong-Wu Yang1, Xiao-Ming Wang3, Yong-Hua Yang4.
Abstract
The high incidence of cancer and the side effects of traditional anticancer drugs motivate the search for new and more effective anticancer drugs. In this study, we synthesized 17 kinds of aryl dihydrothiazol acyl shikonin ester derivatives and evaluated their anticancer activity through MTT assay. Among them, C13 showed better antiproliferation activity with IC50=3.14 ± 0.21 μM against HeLa cells than shikonin (IC50=5.75 ± 0.47 μM). We then performed PI staining assay, cell cycle distribution, and cell apoptosis analysis for C13 and found that it can cause cell arrest in G2/M phase, which leads to cell apoptosis. This derivative can also reduce the adhesive ability of HeLa cells. Docking simulation and confocal microscopy assay results further indicated that C13 could bind well to the tubulin at paclitaxel binding site, leading to tubulin polymerization and mitotic disruption.Entities:
Keywords: 2,3-Dichlorobenzonitrile (PubChem CID: 736567); 4-(Dimethylamino)benzonitrile (PubChem CID: 70967); 4-Chlorobenzonitrile (PubChem CID: 12163); 4-Methoxybenzonitrile (PubChem CID: 70129); 4-Methylbenzonitrile (PubChem CID: 7724); Benzonitrile (PubChem CID: 7505); Colchicine (PubChem CID: 6167); Mitotic arrest; Paclitaxel (PubChem CID: 36314); Shikonin (PubChem CID: 479503); Shikonin ester derivatives; Tubulin polymerization; l-Cysteine (PubChem CID: 5862)
Mesh:
Substances:
Year: 2015 PMID: 25957661 DOI: 10.1016/j.bcp.2015.04.021
Source DB: PubMed Journal: Biochem Pharmacol ISSN: 0006-2952 Impact factor: 5.858